Suppr超能文献

丹皮酚作为成骨细胞中核心结合因子亚基α-1的新型调节剂。

Paeonolide as a Novel Regulator of Core-Binding Factor Subunit Alpha-1 in Bone-Forming Cells.

机构信息

Department of Oral and Maxillofacial Pathology, School of Dentistry, Kyung Hee University, Seoul 02447, Korea.

National Institute for Korean Medicine Development, Gyeongsan 38540, Korea.

出版信息

Int J Mol Sci. 2021 May 6;22(9):4924. doi: 10.3390/ijms22094924.

Abstract

has been extensively used as a traditional medicine with various beneficial effects; paeonolide (PALI) was isolated from its dried roots. This study aimed to investigate the novel effects and mechanisms of PALI in pre-osteoblasts. Here, cell viability was evaluated using an MTT assay. Early and late osteoblast differentiation was examined by analyzing the activity of alkaline phosphatase (ALP) and by staining it with Alizarin red S (ARS). Cell migration was assessed using wound healing and Boyden chamber assays. Western blot and immunofluorescence analyses were used to examine the intracellular signaling pathways and differentiation proteins. PALI (0.1, 1, 10, 30, and 100 μM) showed no cytotoxic or proliferative effects in pre-osteoblasts. In the absence of cytotoxicity, PALI (1, 10, and 30 μM) promoted wound healing and transmigration during osteoblast differentiation. ALP staining demonstrated that PALI (1, 10, and 30 μM) promoted early osteoblast differentiation in a dose-dependent manner, and ARS staining showed an enhanced mineralized nodule formation, a key indicator of late osteoblast differentiation. Additionally, low concentrations of PALI (1 and 10 μM) increased the bone morphogenetic protein (BMP)-Smad1/5/8 and Wnt-β-catenin pathways in osteoblast differentiation. Particularly, PALI (1 and 10 μM) increased the phosphorylation of ERK1/2 compared with BMP2 treatment, an FDA-approved drug for bone diseases. Furthermore, PALI-mediated early and late osteoblast differentiation was abolished in the presence of the ERK1/2 inhibitor U0126. PALI-induced RUNX2 (Cbfa1) expression and nuclear localization were also attenuated by blocking the ERK1/2 pathway during osteoblast differentiation. We suggest that PALI has biologically novel activities, such as enhanced osteoblast differentiation and bone mineralization mainly through the intracellular ERK1/2-RUNX2 signaling pathway, suggesting that PALI might have therapeutic action and aid the treatment and prevention of bone diseases, such as osteoporosis and periodontitis.

摘要

白芍被广泛用作具有多种有益效果的传统药物;丹皮酚(PALI)是从其干根中分离出来的。本研究旨在探讨 PALI 在成骨前体细胞中的新作用和机制。在这里,通过 MTT 测定法评估细胞活力。通过分析碱性磷酸酶(ALP)的活性并用茜素红 S(ARS)染色来检查早期和晚期成骨细胞分化。通过划痕愈合和 Boyden 室测定评估细胞迁移。使用 Western blot 和免疫荧光分析来检查细胞内信号通路和分化蛋白。PALI(0.1、1、10、30 和 100 μM)在成骨前体细胞中没有显示出细胞毒性或增殖作用。在没有细胞毒性的情况下,PALI(1、10 和 30 μM)在成骨细胞分化过程中促进伤口愈合和迁移。ALP 染色表明,PALI(1、10 和 30 μM)以剂量依赖的方式促进早期成骨细胞分化,ARS 染色显示增强的矿化结节形成,这是晚期成骨细胞分化的关键指标。此外,低浓度的 PALI(1 和 10 μM)增加了成骨细胞分化过程中的骨形态发生蛋白(BMP)-Smad1/5/8 和 Wnt-β-catenin 通路。特别是,与 BMP2 处理(一种用于骨骼疾病的 FDA 批准药物)相比,PALI(1 和 10 μM)增加了 ERK1/2 的磷酸化。此外,在存在 ERK1/2 抑制剂 U0126 的情况下,PALI 介导的早期和晚期成骨细胞分化被消除。在成骨细胞分化过程中阻断 ERK1/2 通路也减弱了 PALI 诱导的 RUNX2(Cbfa1)表达和核定位。我们认为,PALI 具有增强成骨细胞分化和骨矿化等生物学新活性,主要通过细胞内 ERK1/2-RUNX2 信号通路,这表明 PALI 可能具有治疗作用,并有助于治疗和预防骨质疏松症和牙周炎等骨骼疾病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1bc/8125120/e3f749d7977e/ijms-22-04924-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验